Inspyr Therapeutics (NSPX) is Resumed by Rodman & Renshaw to “Buy”

Inspyr Therapeutics (NSPX) was Resumed by Rodman & Renshaw to “Buy” and the brokerage firm has set the Price Target at $2. Rodman & Renshaw advised their Clients and Investors in a research report released on Feb 21, 2017.

Inspyr Therapeutics

Add Comment